RCKT
Rocket Pharmaceuticals, Inc.
Price Chart
Latest Quote
$3.35
+0.19 (+6.01%)
Current Price
| Previous Close | $3.16 |
| Open | $3.25 |
| Day High | $3.38 |
| Day Low | $3.19 |
| Volume | 11,287,223 |
Stock Information
| Shares Outstanding | 109.19M |
| Total Debt | $24.76M |
| Cash Equivalents | $144.38M |
| Net Income | $-209.38M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $365.80M |
| EPS (TTM) | $-1.88 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $246.18M |
| Income | $-209.38M |
| Book/sh | $2.18 |
| Cash/sh | $1.32 |
| Employees | 202 |
Financial Ratios
| Quick Ratio | 5.90 |
| Current Ratio | 6.12 |
| Debt/Eq | 10.40 |
Returns & Margins
| ROA | -35.14% |
| ROE | -64.41% |
Ownership
| Insider Ownership | 2.97% |
| Institutional Ownership | 89.87% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -2.88 |
| P/B | 1.54 |
Analyst Data
| Recommendation | buy |
| Target Price | $9.39 |
Technical Indicators
| SMA20 | $2.91 |
| SMA50 | $3.30 |
| SMA200 | $3.54 |
| RSI | 60.00 |
| ATR | 0.1867 |
| Shares Float | 87.64M |
| Short Float | 25.23% |
| Short Ratio | 10.29 |
| Volatility | 0.47 |
| Rel Volume | 3.78 |
Performance History
| Week | +25.94% |
| Month | +14.73% |
| Quarter | -23.69% |
| 6 Months | -2.33% |
| YTD | -3.18% |
| Year | +23.16% |
| 3 Years | -85.63% |
| 5 Years | -92.75% |
| 10 Years | -88.97% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $3.35 | 11,287,200 |
| 2026-06-17 | $3.16 | 4,537,500 |
| 2026-06-16 | $2.80 | 2,171,800 |
| 2026-06-15 | $2.86 | 2,249,400 |
| 2026-06-12 | $2.75 | 2,437,900 |
| 2026-06-11 | $2.66 | 2,556,500 |
| 2026-06-10 | $2.60 | 2,424,000 |
| 2026-06-09 | $2.65 | 2,717,600 |
| 2026-06-08 | $2.70 | 2,359,500 |
| 2026-06-05 | $2.75 | 2,557,800 |
| 2026-06-04 | $2.92 | 2,415,500 |
| 2026-06-03 | $2.92 | 2,896,100 |
| 2026-06-02 | $2.89 | 3,576,600 |
| 2026-06-01 | $3.02 | 2,846,400 |
| 2026-05-29 | $3.07 | 2,261,400 |
| 2026-05-28 | $3.02 | 1,628,900 |
| 2026-05-27 | $2.99 | 1,845,600 |
| 2026-05-26 | $3.00 | 1,980,200 |
| 2026-05-22 | $2.96 | 2,111,500 |
| 2026-05-21 | $3.11 | 2,848,500 |
| 2026-05-20 | $2.97 | 2,619,300 |
| 2026-05-19 | $2.92 | 2,933,100 |
About Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), which is in phase 1; and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is a form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart, which is in preclinical stage. It also develops ex vivo lentiviral (LV) programs, which include programs for Leukocyte Adhesion Deficiency-I (LAD-I), a genetic disorder that causes the immune system to malfunction (RP-L201); Fanconi Anemia (FA), a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells (RP-L102); and Pyruvate Kinase Deficiency (PKD), a red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia (RP-L301). It has license agreements with Centro de Investigaciones EnergÊticas, Medioambientales y TecnolÃŗgicas, Centro de Investigacion Biomedica En Red de Enfermedades Raras, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and Temple University. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.
đ° Latest News
Rocket Pharmaceuticals Inc (RCKT) Got Cash. Whereâs the Stock Going?
Insider Monkey âĸ 2026-05-20T12:35:35Z
Rocket Pharmaceuticals (RCKT) Reports Q1 2026 Net Loss of $47.6M
Insider Monkey âĸ 2026-05-18T04:50:18Z
RCKT Stock Down on Q1 Earnings Miss, Kresladi Launch in Focus
Zacks âĸ 2026-05-11T15:50:00Z
Rocket Pharmaceuticals' Cardiac Programs Updates to Offer 'Strong' Share Price Catalysts, Wedbush Says
MT Newswires âĸ 2026-05-08T16:18:54Z3 Promising Penny Stocks With Market Caps Up To $600M
Simply Wall St. âĸ 2026-05-06T18:05:45Z
Rocket to sell PRV for $180m to advance gene therapy pipeline
Hospital Management âĸ 2026-04-29T09:34:03Z
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease
Zacks âĸ 2026-03-30T16:16:00Z
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Insider Monkey âĸ 2026-03-29T20:54:29Z
Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy
Simply Wall St. âĸ 2026-03-29T17:03:44Z
Promising Penny Stocks To Consider In March 2026
Simply Wall St. âĸ 2026-03-27T18:05:52Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
| Expenses | ||||
| Interest Expense | $1,891,000 | $1,886,000 | $1,875,000 | $1,909,000 |
| Total Expenses | $228,516,000 | $273,205,000 | $259,659,000 | $223,843,000 |
| Other Income Expense | $-3,231,000 | - | - | - |
| Net Non Operating Interest Income Expense | $8,624,000 | $14,459,000 | $14,064,000 | $1,980,000 |
| Interest Expense Non Operating | $1,891,000 | $1,886,000 | $1,875,000 | $1,909,000 |
| Operating Expense | $228,516,000 | $273,205,000 | $259,659,000 | $223,843,000 |
| General And Administrative Expense | $86,501,000 | $101,961,000 | $73,317,000 | $58,773,000 |
| Other Operating Expenses | - | - | - | $-500,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Interest Income | $8,624,000 | $14,459,000 | $14,064,000 | $1,980,000 |
| Interest Income | $10,515,000 | $16,345,000 | $15,939,000 | $3,889,000 |
| Normalized Income | $-219,892,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Income From Continuing And Discontinued Operation | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Total Operating Income As Reported | $-231,747,000 | $-273,205,000 | $-259,659,000 | $-224,343,000 |
| Net Income Common Stockholders | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Income | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Income Including Noncontrolling Interests | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Net Income Continuous Operations | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Pretax Income | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Special Income Charges | $-3,231,000 | $0 | - | - |
| Interest Income Non Operating | $10,515,000 | $16,345,000 | $15,939,000 | $3,889,000 |
| Operating Income | $-228,516,000 | $-273,205,000 | $-259,659,000 | $-223,843,000 |
| Per Share | ||||
| Diluted EPS | $-2.01 | $-2.73 | $-2.92 | $-3.26 |
| Basic EPS | $-2.01 | $-2.73 | $-2.92 | $-3.26 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-206,976,000 | $-247,485,000 | $-236,622,000 | $-213,688,000 |
| Total Unusual Items | $-3,231,000 | $0 | - | - |
| Total Unusual Items Excluding Goodwill | $-3,231,000 | $0 | - | - |
| Reconciled Depreciation | $11,025,000 | $9,375,000 | $7,098,000 | $6,266,000 |
| EBITDA (Bullshit earnings) | $-210,207,000 | $-247,485,000 | $-236,622,000 | $-213,688,000 |
| EBIT | $-221,232,000 | $-256,860,000 | $-243,720,000 | $-219,954,000 |
| Diluted Average Shares | $111,123,770 | $94,807,773 | $84,009,004 | $68,148,925 |
| Basic Average Shares | $111,123,770 | $94,807,773 | $84,009,004 | $68,148,925 |
| Diluted NI Availto Com Stockholders | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Restructuring And Mergern Acquisition | $3,231,000 | $0 | - | - |
| Research And Development | $142,015,000 | $171,244,000 | $186,342,000 | $165,570,000 |
| Selling General And Administration | $86,501,000 | $101,961,000 | $73,317,000 | $58,773,000 |
| Other Gand A | $86,501,000 | $101,961,000 | $73,317,000 | $58,773,000 |
Fetched: 2026-06-17
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $212,917,000 | $398,930,000 | $428,270,000 | $424,808,000 |
| Total Assets | $330,449,000 | $527,700,000 | $566,341,000 | $551,807,000 |
| Total Non Current Assets | $137,715,000 | $149,517,000 | $188,119,000 | $187,747,000 |
| Other Non Current Assets | $1,340,000 | $1,362,000 | $1,372,000 | $1,340,000 |
| Non Current Prepaid Assets | $482,000 | $529,000 | $533,000 | $608,000 |
| Goodwill And Other Intangible Assets | $64,304,000 | $64,304,000 | $64,304,000 | $64,878,000 |
| Other Intangible Assets | $25,150,000 | $25,150,000 | $25,150,000 | $25,724,000 |
| Current Assets | $192,734,000 | $378,183,000 | $378,222,000 | $364,060,000 |
| Other Current Assets | $3,805,000 | $5,847,000 | $5,047,000 | $7,666,000 |
| Cash Cash Equivalents And Short Term Investments | $188,929,000 | $372,336,000 | $373,175,000 | $356,394,000 |
| Cash And Cash Equivalents | $77,558,000 | $163,635,000 | $55,904,000 | $140,517,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $24,877,000 | $25,498,000 | $25,042,000 | $22,866,000 |
| Long Term Debt And Capital Lease Obligation | $21,962,000 | $22,641,000 | $22,326,000 | $20,357,000 |
| Current Debt And Capital Lease Obligation | $2,915,000 | $2,857,000 | $2,716,000 | $2,509,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $53,228,000 | $64,466,000 | $73,767,000 | $62,121,000 |
| Total Non Current Liabilities Net Minority Interest | $23,022,000 | $23,782,000 | $25,262,000 | $22,952,000 |
| Other Non Current Liabilities | $1,060,000 | $1,141,000 | $2,936,000 | $2,595,000 |
| Current Liabilities | $30,206,000 | $40,684,000 | $48,505,000 | $39,169,000 |
| Payables And Accrued Expenses | $14,997,000 | $25,883,000 | $35,859,000 | $26,654,000 |
| Payables | $46,000 | - | $13,137,000 | $597,000 |
| Other Payable | $46,000 | - | $13,137,000 | $597,000 |
| Interest Payable | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Total Equity Gross Minority Interest | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Stockholders Equity | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Gains Losses Not Affecting Retained Earnings | $-31,000 | $66,000 | $319,000 | $-357,000 |
| Other Equity Adjustments | $-31,000 | $66,000 | $319,000 | $-357,000 |
| Retained Earnings | $-1,441,239,000 | $-1,218,116,000 | $-959,370,000 | $-713,775,000 |
| Other | ||||
| Ordinary Shares Number | $108,319,783 | $106,453,818 | $90,282,267 | $79,120,741 |
| Share Issued | $108,319,783 | $106,453,818 | $90,282,267 | $79,123,312 |
| Tangible Book Value | $212,917,000 | $398,930,000 | $428,270,000 | $424,808,000 |
| Invested Capital | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Working Capital | $162,528,000 | $337,499,000 | $329,717,000 | $324,891,000 |
| Capital Lease Obligations | $24,877,000 | $25,498,000 | $25,042,000 | $22,866,000 |
| Total Capitalization | $277,221,000 | $463,234,000 | $492,574,000 | $489,686,000 |
| Additional Paid In Capital | $1,717,408,000 | $1,680,219,000 | $1,450,722,000 | $1,203,074,000 |
| Capital Stock | $1,083,000 | $1,065,000 | $903,000 | $791,000 |
| Common Stock | $1,083,000 | $1,065,000 | $903,000 | $791,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $21,962,000 | $22,641,000 | $22,326,000 | $20,357,000 |
| Current Capital Lease Obligation | $2,915,000 | $2,857,000 | $2,716,000 | $2,509,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $12,294,000 | $11,944,000 | $9,930,000 | $10,006,000 |
| Current Accrued Expenses | $14,951,000 | $25,883,000 | $22,722,000 | $26,057,000 |
| Goodwill | $39,154,000 | $39,154,000 | $39,154,000 | $39,154,000 |
| Net PPE | $71,589,000 | $83,322,000 | $87,590,000 | $77,645,000 |
| Accumulated Depreciation | $-29,123,000 | $-21,253,000 | $-14,032,000 | $-9,093,000 |
| Gross PPE | $100,712,000 | $104,575,000 | $101,622,000 | $86,738,000 |
| Leases | $7,327,000 | $7,282,000 | $6,723,000 | $589,000 |
| Other Properties | $75,557,000 | $78,741,000 | $77,650,000 | $70,541,000 |
| Machinery Furniture Equipment | $17,828,000 | $18,552,000 | $17,249,000 | $15,608,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $111,371,000 | $208,701,000 | $317,271,000 | $215,877,000 |
| Investments And Advances | - | $0 | $34,320,000 | $43,276,000 |
| Treasury Stock | - | - | $0 | $47,000 |
| Treasury Shares Number | - | - | - | $2,571 |
Fetched: 2026-06-17
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-190,454,000 | $-215,586,000 | $-211,388,000 | $-186,761,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-190,014,000 | $-209,724,000 | $-194,916,000 | $-178,142,000 |
| Cash Flow From Continuing Operating Activities | $-190,014,000 | $-209,724,000 | $-194,916,000 | $-178,142,000 |
| Operating Gains Losses | - | $-1,876,000 | $-364,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-440,000 | $-5,862,000 | $-16,472,000 | $-8,619,000 |
| Investing Cash Flow | $103,767,000 | $131,706,000 | $-98,066,000 | $-69,326,000 |
| Cash Flow From Continuing Investing Activities | $103,767,000 | $131,706,000 | $-98,066,000 | $-69,326,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-67,000 | $0 | $0 | $-47,000 |
| Issuance Of Capital Stock | $0 | $185,739,000 | $208,394,000 | $155,335,000 |
| Financing Cash Flow | $148,000 | $185,739,000 | $208,401,000 | $155,288,000 |
| Cash Flow From Continuing Financing Activities | $148,000 | $185,739,000 | $208,401,000 | $155,288,000 |
| Net Other Financing Charges | $215,000 | - | - | - |
| Net Common Stock Issuance | $-67,000 | $185,739,000 | $208,394,000 | $155,288,000 |
| Common Stock Issuance | $0 | $185,739,000 | $208,394,000 | $155,335,000 |
| Other | ||||
| End Cash Position | $78,898,000 | $164,997,000 | $57,276,000 | $141,857,000 |
| Beginning Cash Position | $164,997,000 | $57,276,000 | $141,857,000 | $234,037,000 |
| Changes In Cash | $-86,099,000 | $107,721,000 | $-84,581,000 | $-92,180,000 |
| Common Stock Payments | $-67,000 | $0 | $0 | $-47,000 |
| Net Investment Purchase And Sale | $104,207,000 | $137,568,000 | $-81,594,000 | $-103,433,000 |
| Sale Of Investment | $380,760,000 | $383,454,000 | $309,326,000 | $272,894,000 |
| Purchase Of Investment | $-276,553,000 | $-245,886,000 | $-390,920,000 | $-376,327,000 |
| Net PPE Purchase And Sale | $-440,000 | $-5,862,000 | $-16,472,000 | $-8,619,000 |
| Purchase Of PPE | $-440,000 | $-5,862,000 | $-16,472,000 | $-8,619,000 |
| Change In Working Capital | $-8,263,000 | $5,671,000 | $13,822,000 | $6,076,000 |
| Change In Other Current Liabilities | $-1,000 | $265,000 | $981,000 | $-5,000 |
| Change In Payables And Accrued Expense | $-10,351,000 | $6,067,000 | $10,147,000 | $9,674,000 |
| Change In Prepaid Assets | $2,089,000 | $-661,000 | $2,694,000 | $-3,593,000 |
| Stock Based Compensation | $37,059,000 | $43,920,000 | $39,406,000 | $31,009,000 |
| Asset Impairment Charge | $262,000 | $0 | $885,000 | $236,000 |
| Amortization Of Securities | $-6,974,000 | $-8,068,000 | $-10,168,000 | $134,000 |
| Depreciation Amortization Depletion | $11,025,000 | $9,375,000 | $7,098,000 | $6,266,000 |
| Depreciation And Amortization | $11,025,000 | $9,375,000 | $7,098,000 | $6,266,000 |
| Depreciation | $11,025,000 | $9,375,000 | $7,098,000 | $6,266,000 |
| Net Income From Continuing Operations | $-223,123,000 | $-258,746,000 | $-245,595,000 | $-221,863,000 |
| Proceeds From Stock Option Exercised | - | $0 | $7,000 | $0 |
| Net Business Purchase And Sale | - | $0 | $0 | $42,726,000 |
| Sale Of Business | - | $0 | $0 | $42,726,000 |
| Gain Loss On Investment Securities | - | $-1,876,000 | $-364,000 | - |
| Interest Paid Supplemental Data | - | - | - | $0 |
| Income Tax Paid Supplemental Data | - | - | - | - |
| Other Non Cash Items | - | - | - | - |
Fetched: 2026-06-17